Stocktoria
Traws Pharma, Inc. TRAW
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-07-25
Traws Pharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $226,000 | $226,000 | $226,000 | $226,000 |
| R&D expense | — | — | $11.4M | $11.4M | $7.3M |
| Operating income | -$17.9M | -$142.4M | -$20.3M | -$19.6M | -$16.5M |
| Net income | $9.2M | -$166.5M | -$18.9M | -$19.0M | -$16.2M |
| EPS (diluted) | $0.82 | $-35.21 | $-22.57 | $-0.91 | $-0.96 |
| Operating cash flow | -$18.2M | -$29.8M | -$17.9M | -$16.3M | -$19.5M |
| Free cash flow | — | — | -$17.9M | — | — |
| Cash & equivalents | — | — | $20.6M | $38.5M | — |
| Total assets | $10.6M | $25.0M | $22.7M | $39.4M | $55.5M |
| Total liabilities | $11.2M | $56.6M | $12.0M | $11.1M | $9.4M |
| Shareholders' equity | -$629,000 | -$31.6M | $10.7M | $28.3M | $46.1M |
Source: SEC EDGAR filings · CIK 0001130598 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.